{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00542:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00542%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004542,
    "timestamp_received": "2026-05-06T15:41:49.953462+00:00Z",
    "timestamp_returned": "2026-05-06T15:41:49.958004+00:00Z",
    "trace_id": "0aa9ae77-a96e-40c5-b2af-15fb04bf283e"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-27"
  },
  "data": [
    {
      "id": "ind:hse.00542:a",
      "indication": "In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.",
      "initial_approval_date": "2019-02-05",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",
      "raw_biomarkers": null,
      "raw_cancer_type": "follicular lymphoma",
      "raw_therapeutics": "rituximab in combination with chemotherapy",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00542",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "riTUXimab 375 mg/m2 Combination Therapy-21 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6642/542_v2a_riTUXimab_375_mgm2_CombinationTherapy.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6642/542_v2a_riTUXimab_375_mgm2_CombinationTherapy.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-06-26",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}